NCT01449370View on ClinicalTrials.gov

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

January 31, 2016

Conditions
Metastatic Solid Tumors
Interventions
DRUG

TAK-117

oral administration of TAK-117, daily and intermittent schedules.

Trial Locations (5)

Unknown

Boston

Detroit

Dallas

Barcelona

Sutton

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY